Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study-Reference-Cited by-同舟云学术

Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study

Published:2024-06-18 Issue: Volume: Page:1-8
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Jia Liu¹^ORCID,Yuequan Shi¹,Jian Fang²,Hongmin Lu³,Yongjie Shui⁴,Xiaoyan Liu¹,Minjiang Chen¹,Yan Xu¹,Mengzhao Wang¹

Affiliation:

1. Department of Respiratory & Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

2. Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China

3. Department of Oncology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

4. Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Funder

The National High Level Hospital Clinical Research Funding of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1750743X.2024.2354108

Reference30 articles.

1. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety

2. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

3. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

4. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

5. Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China